Browsing by Author "Carrasco, Elena"

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Anesthesia for electroconvulsive therapy: clinical experience
    (2007) González, Aridane G.; Cortínez, Luis I.; Cuadra F., Juan Carlos de la; Carrasco, Elena; Rioseco, Alonso; Léniz, Pamela Wisnia
    OBJECTIVE: To assess the utility of propofol and succinylcholine in obtaining optimal convulsions and assuring patient safety during electroconvulsive therapy. PATIENTS AND METHODS: This was a prospective observational study of patients undergoing electroconvulsive therapy under general anesthesia with propofol and succinylcholine. We recorded patient characteristics, doses of propofol and succinylcholine, electroencephalographically-recorded duration of convulsions, and complications. Descriptive statistics were compiled and the data were subjected to analysis of correlations, comparison with the Student t test for independent samples, the Mann-Whitney U test, and analysis of variance. RESULTS: We studied 108 patients, 62% women and 38% men, 80% classified as ASA 1 and 20% as ASA 2. The patients underwent 844 sessions of electroconvulsive therapy; their mean (SD) age was 39.95 (18.09) years. The doses of propofol and succinylcholine were 1.34 (0.32) mgxkg(-1) and 1.35 (0.26) mgxkg(-1), respectively. The mean recorded duration of the first convulsion (29.87 [22.42] seconds) was negatively correlated with age (r = -0.12) and unrelated to propofol dose (r = 0.06) or body weight (r = 0.02). Male and schizophrenic patients had longer-lasting convulsions (P < .01). Cardiovascular complications occurred in 2.4% and psychomotor agitation in 1.4%; there were no respiratory complications, musculoskeletal injuries, nausea, or vomiting. CONCLUSIONS: Electroconvulsive therapy can be safely applied in an operating room or similar space undergeneral anesthesia and with a neuromuscular blockade in order to prevent psychological or musculoskeletal trauma. Propofol did not affect the convulsions at the dosages administered.
  • No Thumbnail Available
    Item
    Anesthesia for electroconvulsive therapy: clinical experience
    (Wiley, 2007) González, Aridane G.; Cortínez, Luis I.; Cuadra F., Juan Carlos de la; Carrasco, Elena; Rioseco, Alonso; Léniz, Pamela Wisnia
    OBJECTIVE: To assess the utility of propofol and succinylcholine in obtaining optimal convulsions and assuring patient safety during electroconvulsive therapy. PATIENTS AND METHODS: This was a prospective observational study of patients undergoing electroconvulsive therapy under general anesthesia with propofol and succinylcholine. We recorded patient characteristics, doses of propofol and succinylcholine, electroencephalographically-recorded duration of convulsions, and complications. Descriptive statistics were compiled and the data were subjected to analysis of correlations, comparison with the Student t test for independent samples, the Mann-Whitney U test, and analysis of variance. RESULTS: We studied 108 patients, 62% women and 38% men, 80% classified as ASA 1 and 20% as ASA 2. The patients underwent 844 sessions of electroconvulsive therapy; their mean (SD) age was 39.95 (18.09) years. The doses of propofol and succinylcholine were 1.34 (0.32) mgxkg(-1) and 1.35 (0.26) mgxkg(-1), respectively. The mean recorded duration of the first convulsion (29.87 [22.42] seconds) was negatively correlated with age (r = -0.12) and unrelated to propofol dose (r = 0.06) or body weight (r = 0.02). Male and schizophrenic patients had longer-lasting convulsions (P < .01). Cardiovascular complications occurred in 2.4% and psychomotor agitation in 1.4%; there were no respiratory complications, musculoskeletal injuries, nausea, or vomiting. CONCLUSIONS: Electroconvulsive therapy can be safely applied in an operating room or similar space undergeneral anesthesia and with a neuromuscular blockade in order to prevent psychological or musculoskeletal trauma. Propofol did not affect the convulsions at the dosages administered.
  • No Thumbnail Available
    Item
    Associations of the CTLA-4 polymorphism with type 1 diabetes in Chilean population: case-parent design
    (2009) Angel, Bárbara; Balic, Iván; Santos Martín, José Luis; Codner, Ethel; Carrasco, Elena; Pérez-Bravo, Francisco
    CTLA-4 plays a key role in T cells regulation. We analysed the CTLA-4 +49A/G and -318C/T polymorphisms in 178 cases of type 1 diabetes and their parents (534 individuals) from Santiago, Chile. A significant overall association with T1D (p = 0.028) was observed, possibly due to an overtransmission of the G-T haplotype. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
  • No Thumbnail Available
    Item
    Second Consensus of the Chilean Society of Endocrinology and Diabetes about insulin resistance
    (SOC MEDICA SANTIAGO, 2015) Pollak, Felipe; Araya, Veronica; Lanas, Alejandra; Sapunar, Jorge; Arrese, Marco; Gloria Aylwin, Carmen; Gloria Bezanilla, Carmen; Carrasco, Elena; Carrasco, Fernando; Codner, Ethel; Diaz, Erik; Durruty, Pilar; Galgani, Jose; Garcia, Hernan; Lahsen, Rodolfo; Liberman, Claudio; Lopez, Gloria; Maiz, Alberto; Mujica, Veronica; Poniachik, Jaime; Sir, Teresa; Soto, Nestor; Valderas, Juan; Villaseca, Paulina; Zavala, Carlos
    Insulin resistance is a prevalent condition commonly associated with unhealthy lifestyles. It affects several metabolic pathways, increasing risk of abnormalities at different organ levels. Thus, diverse medical specialties should be involved in its diagnosis and treatment. With the purpose of unifying criteria about this condition, a scientific-based consensus was elaborated. A questionnaire including the most important topics such as cardio-metabolic risk, non-alcoholic fatty liver disease and polycystic ovary syndrome, was designed and sent to national experts. When no agreement among them was achieved, the Delphi methodology was applied. The main conclusions reached are that clinical findings are critical for the diagnosis of insulin resistance, not being necessary blood testing. Acquisition of a healthy lifestyle is the most important therapeutic tool. Insulin-sensitizing drugs should be prescribed to individuals at high risk of disease according to clinically validated outcomes. There are specific recommendations for pregnant women, children, adolescents and older people.